Patents Assigned to HYpharm GmbH
-
Publication number: 20220265782Abstract: The present invention relates to compositions comprising a therapeutic protein with enhanced stability, which comprise a piperazine- or morpholine-containing zwitterionic buffering substance, such as HEPES, in particular when used out of the common pH range. The compositions of the invention are particularly useful for topical administration The present invention further relates to the use of said compositions for treating bacterial infections, e.g. bacterial infections caused by Staphylococcus aureus such as methicillin-resistant Staphylococcus aureus (MRSA). The present invention further relates to the use of said compositions for preventing or eliminating nasal bacterial colonization or bacterial colonization of the skin.Type: ApplicationFiled: July 16, 2020Publication date: August 25, 2022Applicants: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN, HYPHARM GMBHInventors: Gerhard WINTER, Simon EISELE, Sonja MOLINARO, Wolfgang MUTTER
-
Patent number: 11116824Abstract: The present invention relates to assays, kits and oligonucleotides for the detection of Pseudomonas aeruginosa for a fast, sensitive and reliable detection of Pseudomonas aeruginosa in a species- and serotype-specific manner. In particular, the present invention provides an assay for the serotype-specific detection of Pseudomonas aeruginosa, a kit for the serotype-specific detection of Pseudomonas aeruginosa, as well as oligonucleotides useful in such assay or kit. The present invention further relates to the use of Pseudomonas aeruginosa serotype specific antibodies for serotype specific treatment of Pseudomonas aeruginosa infection in a patient detected for said specific Pseudomonas aeruginosa serotype with such an assay or kit.Type: GrantFiled: June 27, 2019Date of Patent: September 14, 2021Assignee: HYpharm GmbHInventors: Holger Grallert, Sonja Molinaro
-
Patent number: 10655113Abstract: The present invention relates to novel methods of generating and screening for chimeric polypeptides, which can be used in the treatment and prophylaxis of pathogenic bacterial contamination, colonisation and infection. The novel methods are based on random recombination of protein domains, and the chimeric polypeptides obtainable by the methods according to the invention are characterized in that they comprise at least one enzymatic active domain (EAD) and at least one cell binding domain (CBD). The present invention also relates to a library of chimeric polypeptides obtainable by the methods of the present invention.Type: GrantFiled: April 22, 2019Date of Patent: May 19, 2020Assignee: HYPHARM GMBHInventors: Anna Scherzinger, Sonja Molinaro, Bernd Buchberger
-
Publication number: 20190249156Abstract: The present invention relates to novel methods of generating and screening for chimeric polypeptides, which can be used in the treatment and prophylaxis of pathogenic bacterial contamination, colonisation and infection. The novel methods are based on random recombination of protein domains, and the chimeric polypeptides obtainable by the methods according to the invention are characterized in that they comprise at least one enzymatic active domain (EAD) and at least one cell binding domain (CBD). The present invention also relates to a library of chimeric polypeptides obtainable by the methods of the present invention.Type: ApplicationFiled: April 22, 2019Publication date: August 15, 2019Applicant: HYPHARM GMBHInventors: Anna SCHERZINGER, Sonja MOLINARO, Bernd BUCHBERGER
-
Patent number: 10342857Abstract: The present invention relates to assays, kits and oligonucleotides for the detection of Pseudomonas aeruginosa for a fast, sensitive and reliable detection of Pseudomonas aeruginosa in a species- and serotype-specific manner. In particular, the present invention provides an assay for the serotype-specific detection of Pseudomonas aeruginosa, a kit for the serotype-specific detection of Pseudomonas aeruginosa, as well as oligonucleotides useful in such assay or kit. The present invention further relates to the use of Pseudomonas aeruginosa serotype specific antibodies for serotype specific treatment of Pseudomonas aeruginosa infection in a patient detected for said specific Pseudomonas aeruginosa serotype with such an assay or kit.Type: GrantFiled: June 15, 2018Date of Patent: July 9, 2019Assignee: HYPHARM GMBHInventors: Holger Grallert, Sonja Molinaro
-
Patent number: 10301607Abstract: The present invention relates to novel methods of generating and screening for chimeric polypeptides, which can be used in the treatment and prophylaxis of pathogenic bacterial contamination, colonization and infection. The novel methods are based on random recombination of protein domains, and the chimeric polypeptides obtainable by the methods according to the invention are characterized in that they comprise at least one enzymatic active domain (EAD) and at least one cell binding domain (CBD). The present invention also relates to a library of chimeric polypeptides obtainable by the methods of the present invention.Type: GrantFiled: January 20, 2016Date of Patent: May 28, 2019Assignee: HYPHARM GMBHInventors: Anna Scherzinger, Sonja Molinaro, Bernd Buchberger
-
Patent number: 10022430Abstract: The present invention relates to chimeric polypeptides comprising a first portion, which comprises a bacteriocin cell wall-binding domain (CBD) and a second portion, which comprises an enzymatic active domain (EAD) selected from the lytic domain of a bacteriophage lysin, a bacteriocin and a bacterial autolysin. Provided are such chimeric polypeptides and variants and fragments thereof, nucleic acids encoding the same, vectors carrying such nucleic acids and host cells transformed or transfected with such vectors. The chimeric polypeptides of the present invention are useful for the reduction of certain bacterial populations, including methods and compositions for the treatment of various bacterial infections. For example, chimeric polypeptides of the present invention have been shown to effectively kill various bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), as well as other human pathogens.Type: GrantFiled: May 11, 2015Date of Patent: July 17, 2018Assignee: HYpharm GmbHInventors: Holger Grallert, Sonja Molinaro